Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146720 | PMC |
| http://dx.doi.org/10.1093/cid/ciw636 | DOI Listing |
Publication Analysis
Top Keywords
ceftazidime-avibactam resistance
8
patients treated
8
carbapenem-resistant enterobacteriaceae
8
clinical outcomes
4
outcomes drug
4
drug toxicity
4
toxicity emergence
4
emergence ceftazidime-avibactam
4
resistance patients
4
treated carbapenem-resistant
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!